Is pentosan polysulfate sodium (used for interstitial cystitis) associated with neurological symptoms, such as ocular toxicity or peripheral neuropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pentosan Polysulfate and Neurological Symptoms: Ocular Toxicity Risk

Yes, pentosan polysulfate sodium (PPS) is definitively associated with vision-threatening retinal maculopathy, which represents the primary neurological/sensory toxicity of concern with this medication. 1

Primary Neurological Manifestation: Retinal Maculopathy

The most significant and well-documented neurological complication of PPS is a unique retinal pigmentary maculopathy that can cause irreversible vision damage. 1 This association is strong enough that the FDA approved a new warning label in June 2020 specifically addressing this risk. 1

Clinical Presentation of PPS Maculopathy

The visual symptoms patients experience include:

  • Difficulty reading 1
  • Slow adjustment to low or reduced light environments (prolonged dark adaptation) 1, 2
  • Blurred vision 1
  • Relative preservation of visual acuity initially, despite significant retinal changes 2

Dose-Dependent Risk Profile

The prevalence of maculopathy varies widely but is directly related to cumulative PPS exposure. 1 A 2025 meta-analysis of 411,098 patients demonstrated a statistically significant increased risk of maculopathy (HR 1.678,95% CI 1.066-2.642), with risk increasing in both short-term (<5 years: HR 1.285) and long-term (>5 years: HR 1.341) users. 3

The evidence base evolved from initial case reports and small case series to large retrospective cohort studies that confirmed the association. 1 A 2022 FDA adverse event analysis found maculopathy was proportionately more common among PPS users compared to other interstitial cystitis drugs (3.4% vs 0.03%, PRR 1.21). 4

Mandatory Screening Protocol

All patients considering or currently taking PPS must undergo structured ophthalmologic surveillance per FDA requirements: 1

  1. Obtain detailed ophthalmologic history before starting PPS 1, 5
  2. Perform comprehensive baseline retinal examination for patients with preexisting eye conditions 1, 5
  3. Conduct retinal examination within 6 months of initiating treatment 1, 5
  4. Continue periodic retinal examinations throughout treatment 1, 5
  5. If pigmentary changes develop, reevaluate risks versus benefits immediately, as changes may be irreversible 1, 5

Diagnostic Imaging Findings

Fundus autofluorescence most clearly depicts PPS maculopathy, showing a distinctive pattern of hypo- and hyperautofluorescent spots in the posterior pole, sometimes with a characteristic peripapillary hypoautofluorescent halo. 2 Optical coherence tomography reveals focal RPE thickening with pigment clumps, and near-infrared reflectance may aid in early detection. 6, 2

Progressive Nature and Irreversibility

A critical pitfall is assuming that stopping PPS will halt progression—the maculopathy can continue to worsen even after drug cessation. 2, 3 Complications include RPE atrophy, cystoid macular edema, and macular neovascularization, potentially resulting in central vision loss. 2

Other Neurological Symptoms: Minimal Evidence

Unlike the well-established ocular toxicity, there is no documented association between PPS and peripheral neuropathy or other systemic neurological symptoms in the provided evidence. The neurological risk is confined to the retinal/visual system. 1, 5

Clinical Decision Algorithm

When prescribing PPS:

  • Discuss the specific risk of irreversible macular damage before initiating therapy 1, 5
  • Minimize dose and duration of PPS use to reduce cumulative exposure 2
  • Use PPS as part of multimodal therapy, not monotherapy 1, 5
  • Consider alternative treatments (amitriptyline, cimetidine, hydroxyzine) for patients with preexisting retinal disease 1

For patients already on PPS who develop visual symptoms:

  • Discontinue PPS immediately 6, 2
  • Refer urgently to ophthalmology for multimodal retinal imaging 6, 2
  • Do not restart PPS if maculopathy is confirmed 6, 2

Context: PPS Efficacy vs. Risk

The American Urological Association gives PPS only Grade B evidence for efficacy, with contradictory trial results—some showing no benefit over placebo. 1 Given this equivocal efficacy profile combined with the risk of irreversible vision loss, the risk-benefit calculation for PPS has become increasingly unfavorable, particularly for long-term use. 1, 5

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Research

Pentosan polysulfate maculopathy.

Survey of ophthalmology, 2022

5
Guideline

Indication of Ellura (Pentosan Polysulfate Sodium) for Interstitial Cystitis/Bladder Pain Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6
Research

Case Report: Pentosan Polysulfate Sodium Maculopathy Originally Diagnosed as Pattern Macular Dystrophy.

Optometry and vision science : official publication of the American Academy of Optometry, 2021

Related Questions

How do I manage an adult with epistaxis, including first‑line pressure, topical vasoconstrictors, cautery, packing, and criteria for ENT referral?
How should onychocryptosis be managed?
What are the recommended blood pressure targets and antihypertensive treatment strategies for a hypertensive patient with a neurologic disorder such as acute ischemic stroke (with or without thrombolysis), intracerebral hemorrhage, subarachnoid hemorrhage, chronic cerebrovascular disease, Parkinson’s disease with orthostatic hypotension, or resistant hypertension?
How should I manage a patient with hypertensive urgency (systolic ≥180 mm Hg or diastolic ≥110 mm Hg without acute target‑organ damage), including first‑line oral therapy, dosing, monitoring, and when to use intravenous agents?
In a cystic fibrosis patient on daily prophylactic antibiotics and doxycycline for rosacea who presents with three weeks of yellow‑colored diarrhea and abdominal discomfort, what diagnostic tests should be ordered?
What is the optimal ADHD medication for an adult with postural orthostatic tachycardia syndrome (POTS) and a history of seizures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question